Paragraph IV notice management, explained.

What a Paragraph IV notice is, and why one letter can hold a generic off the market for 30 months

One Paragraph IV notice letter, from an Orange Book listing to a stay on approval

1. The patent is listedThe brand gives FDA its patent information, and the patent appears in the Orange Book. Only listed patents can bring the stay.
2. The generic certifiesThe ANDA says, patent by patent, how the company will treat each one. A Paragraph IV answer says invalid or not infringed.
3. The notice arrivesA letter with a detailed statement reaches each patent owner and the brand's application holder. The day after receipt is day 1. This guide is mostly about this step.
4. Counsel decidesPatent counsel weighs the claims, the arguments, the venue (which court can hear the case) and the cost, and decides whether to sue within the window.
5. The stay runs, or it doesn'tA timely suit holds FDA's approval for up to 30 months. The case is then tried or settled. No suit means no stay.

The Orange Book is FDA's list, "Approved Drug Products With Therapeutic Equivalence Evaluations". The application holder is the company that holds the brand's new drug application, or NDA, at FDA. The stay holds FDA's approval. It does not stop the generic company from preparing.

The Paragraph IV clock: four facts that surprise newcomers

ANDA, Orange Book, detailed statement, stay: the notice letter's vocabulary

Fourteen terms are defined in the one-page summary.

Four answers a generic can give to each Orange Book patent, and why only the fourth starts a fight

In shortFor every listed patent, the ANDA must certify one of four things, which the statute numbers I to IV. Three of them accept the patent's date. The fourth, Paragraph IV, says the patent is invalid or will not be infringed. It brings the notice letter, the 45-day window and possibly a lawsuit. A separate route, the section viii statement, carves a patented use out of the label.

One application can mix these answers. In this guide's fictional example, Jorvane Generics files Paragraph IV on the '772 and '418 patents and Paragraph III on the '207 compound patent, so it accepts that it must wait for the '207 while it attacks the other two. The Supreme Court described the choice in June 2026: a company taking the Paragraph IV route "wagers that it will eventually be able to" market for all approved uses, while section viii is the "less confrontational path".2

The 180-day prize that makes generic companies race to file first

A generic company picks this fight for a prize. The first company or companies to submit a substantially complete ANDA with a Paragraph IV certification are generally eligible for 180 days in which later filers cannot be approved.8,3 Later filers wait until 180 days after the first commercial marketing by any first applicant.3 The prize can be lost: the statute lists forfeiture events, such as failing to market by set dates.3

This explains a pattern the patent team sees at once. A product's first notices often arrive together, and a brand can receive several letters in the same weeks.

Section 505(b)(2) applications, which rely partly on studies the applicant did not run, follow a parallel notice rule in 21 CFR 314.52, and FDA's 45-day computation in 314.107 covers both.4 This guide uses the ANDA words throughout.

The 45-day clock and the 30-month stay, exactly as 21 USC 355(j) and FDA's rule state them

In shortThe statute gives 45 days from the date the notice is received, and 30 months from that same date. FDA's rule adds the counting: day 1 is the day after receipt, a 45th day on a weekend or federal holiday moves to the next ordinary day, each recipient has its own clock, and the 30 months run from the later receipt. The statute has more ways the 30 months can end early or change.

We read FDA's rules in the 2025 CFR edition, revised as of April 1, 2025. Its source notes date 314.107 from October 6, 2016, and show 314.95 last amended February 28, 2019.7,4 One Federal Register search found no later change. That does not rule one out, so have counsel confirm.

Counting real calendars: three receipts, three last days

What ends the 30 months early, or stretches them

The 30 months are a ceiling that courts can move, and they can be overtaken by a decision. The statute and FDA's rule list these cases:3,4

The new chemical entity exception: when 30 months become 7.5 years from approval

A brand-new active ingredient has five years in which no ANDA may be submitted, except that one with a Paragraph IV certification may come in after four years. If suit is brought during the year beginning 48 months after approval, the stay "shall be extended by such amount of time (if any) which is required for seven and one-half years to have elapsed from the date of approval".3

The arithmetic, on an illustrative date: a drug approved on June 1, 2022 can draw a Paragraph IV filing after June 1, 2026, with the notice following FDA's acknowledgment. A notice received on October 7, 2026 and a timely suit give a plain 30 months to April 7, 2029. The extension carries it to December 1, 2029.

After suit: the filer tells FDA, and an owner can waive the window in writing

The applicant must tell FDA in writing within 14 days of any suit filed within the window, and the patent owner or application holder may also tell FDA. If FDA hears nothing by the later of day 45 or the end of its review, the application may be approved once the applicant confirms no suit was filed.4 An owner that does not intend to sue may also file a written waiver, in the exact form the rule prints, before the 45 days elapse.4

From Hatch-Waxman in 1984 to Hikma in 2026: the laws and rulings a notice letter sits under

In shortThe system dates from the Hatch-Waxman Amendments of 1984. FDA's notice and counting rules, as the 2025 CFR edition prints them, date from 2016. Three recent changes matter most. The Federal Circuit, the US appeals court for patent cases, ordered device patents off the Orange Book while the Federal Trade Commission (FTC) pressed companies to withdraw others. In June 2026 the Supreme Court reversed an inducement ruling against a skinny label (inducement means actively encouraging someone else's infringement). And the Patent Office has changed how petitions for inter partes review (IPR), an attack on a patent at that office, get instituted, or allowed to begin, with a final rule pending.

Checking a notice letter against 21 CFR 314.95: timing, delivery, contents and what a defect does

In shortFDA's rule sets when the letter may be sent, how it must travel, whom it must reach and what it must hold. A letter sent before FDA's acknowledgment is invalid. That much is settled by the rule itself. What a thin detailed statement does to the clock is much less clear. We found no ruling that voids a notice on that ground, FDA does not review a letter's content, and courts have limited who can challenge it. A cautious team notes the defect, keeps counting and lets counsel decide.

A premature notice has no legal effect, according to FDA and two federal courts

The preamble to FDA's 2016 rule, the agency's explanation printed with it, says "Notice of a paragraph IV certification that has been sent prematurely is invalid, and will not be considered to comply with the FD&C Act's notice requirement."9 Courts have acted on this. In SB Pharmco Puerto Rico v. Mutual Pharmaceutical (E.D. Pa. 2008), a notice sent before FDA received the application was "premature and ineffective", in FDA Law Blog's report, and "premature and improper", in the passage a later Delaware opinion quotes. We read that ruling only through those two.20,5

In Merck & Cie v. Watson, a Delaware federal court order of September 25, 2012 recites that a letter "sent absent a received ANDA is of no legal effect" and "does not invoke the 45-day window", and it grants the plaintiffs' motion to dismiss.19 That order came on the patent owners' own motion, on an application that had not been accepted, so read it for what it is.

A thin detailed statement is a harder question, and the safest answer is to keep counting

The rule says the statement must be full and detailed. It also says that if the section's requirements are met, FDA "will presume the notice to be complete and sufficient" and will count the 45 days.7 FDA will not referee: in 2016 it declined to add "a ministerial review" of notices for compliance, and the Federal Circuit has called the substance of the letter "immaterial to the FDA".9,22

Courts have held back too. The Federal Circuit said in 3M v. Barr (2002) that the appellants there "cannot seek a judicial determination of whether a private party's paragraph IV certification complies" with the notice statute, and in 2012 a Delaware court relied on it to hold that Endo lacked standing, the legal right to raise the point, to challenge service of a notice. We read 3M only as the later Endo opinion quotes it.5 A West Virginia federal court said in 2023 that it "possesses no authority to penalize any perceived deficiencies" in a notice letter, in a dispute over which defenses the generic could raise, as Crowell & Moring reports it.21

We found no court decision holding that a weak statement voids a notice and stops the clock. On November 3, 2026 we looked in the rule, FDA's 2016 preamble, the opinions cited in this guide, law firm commentary and open web searches. We had no paid case-law database, so counsel's research should go further.

Waiting for a ruling that your letter was too thin, with the stay at stake, is a bet few counsel would choose lightly. A cautious team records the defect in writing, keeps the date on the docket and lets counsel decide what to say about it. Your own complaint gets a little room: in Endo v. Mylan, a complaint with a pleading defect, filed in time, still counted as an action that triggers the stay.5

Reading a detailed statement claim by claim: the six grounds, and how much of it is new

In shortA detailed statement attacks patent claims on a short list of grounds: not infringed, no inducement, anticipated, obvious, indefinite or not described, double patenting. Most of the first reading is sorting. Which claim, which ground, which reference, and has anyone answered it before? No source publishes how often arguments repeat, so measure it on your own letters.

A worked argument: 76% at 12 hours against a claim that says at least 80%

In the fictional example, claim 9 of the '418 patent covers a tablet "releasing at least 80% at 12 hours". Jorvane's letter says its tablet releases 76% at 12 hours. On its face, that places the product four points under the claim, and the argument is about facts in Jorvane's own application. Brightwell Pharma argued 70% two days earlier, on the same claim, and that is unanswered too.

No earlier brief settles a question like this. The next step is to ask for the dissolution data, the lab results showing how fast the tablet releases its drug, under the offer of confidential access. Finding that out early is why a team separates what is new from what is repeated.

What the offer of confidential access lets you read, and who may read it

A generic company alleging non-infringement that wants to keep its right to a declaratory judgment must offer "confidential access to the application" for "the sole and limited purpose of evaluating possible infringement".3,7 Asking for access counts as accepting the offer's terms, and those terms become "an enforceable contract". The statute also lets the applicant redact anything of no relevance to infringement.3 So the people who may read the file are limited by the offer, and the fights are often about who those people are. Ask early: reading takes time, and your 45 days are running.

Which patents hold up: outcomes differ sharply by patent type

The clearest published split comes from a study of new drugs approved from 1994 to 2006, for the top fifth by sales. Patents on the active ingredient mostly held, and formulation-only patents mostly fell. It is older data, on the bigger drugs, so use it for the shape of the risk.23 In the fictional example, the '772 is a method patent, the '418 a formulation patent and the '207 a compound patent. That is one reason a team cares which patents draw arguments.

How often generics challenge a brand's patents: 81 in 100 new drugs reaching generic entry, about six years after launch

In shortParagraph IV challenges are routine for any product that sells well. One published dataset of drugs reaching generic entry found 93% of those above $250 million in sales faced one, first arriving about six years after launch, with close to nine challengers each. FDA's own list shows a steady flow of new first challenges, about 50 a year since 2019. Nobody publishes how many notice letters a company receives. You can count your own.

Grabowski and colleagues, 356 new molecular entities with first generic entry from 1995 to 2019, using IQVIA data. A new molecular entity is a drug whose active ingredient FDA had not approved before. These are older cohorts, and we found no later update.

Those first-day clusters are the race for 180-day exclusivity, and each company sends its own letter with its own statement. A team with one product under challenge can see several 45-day clocks running at once, starting on different days. In the fictional example, Jorvane's notice comes two days after Brightwell's, so their last days differ, and so do the two stays: April 5 and April 7, 2029.

ANDA litigation after the notice: New Jersey and Delaware, settlements, and what older court counts show

In shortSince a 2020 appeals ruling, a suit against a US generic company must go where it is incorporated, or where it acted on its application and also has a regular place of business. New Jersey and Delaware still take most ANDA cases, and New Jersey led in 2024. Most public outcome numbers are old. Many cases settle, and those settlements are filed with the FTC and the Justice Department and can face antitrust review.

Where you can sue is a question to settle before day 45

In November 2020, in Valeant v. Mylan, the Federal Circuit held that venue, the place a suit may be filed, in these cases "must be predicated on past acts of infringement", and that those acts "occur only in districts where actions related to the ANDA submission occur". The general patent venue statute still applies, so a US company can be sued where it is incorporated, or where it committed those acts and has a regular and established place of business. The Indian defendant in that case was, undisputed, open to suit in any district.11

A year later, in Celgene v. Mylan, the court held that "Sending a paragraph IV notice letter does not fall within 'submitting' the ANDA", so receiving the letter in New Jersey did not put the suit there.22

In the fictional example, Jorvane is a Delaware company, so Delaware is available. Where a filer has a different home, the choice takes time, and that time comes out of the 45 days. A wrong choice is costly to find out late: a new suit after a venue dismissal falls outside the window, and whether the first filing still holds the stay is a question for counsel.

Filings themselves have fallen from their peak. Fish & Richardson counted 479 ANDA cases in 2015 and an estimated 255 in 2023, on Docket Navigator data through December 1, 2023.25 WIT Legal, on its own tracking, counted 320 new ANDA cases in 2025, across 124 product groups; its venue table sits in a report we did not read.26

Judges also shape how much of a statement you must fight at trial: the same review notes one judge's limits of 10 claims per patent and 12 prior art references, the earlier publications used against a patent, per patent, with higher totals or stepped narrowing from other judges.25

The only full public count of outcomes is from 2002

FTC's 2002 study looked at first generic filers on 104 drug products. The brand sued in 72%, and in the cases decided by a court the generic won 22 of 30. Suit to district court decision took an average of 25 months and 13 days.27 These numbers predate today's rules and today's mix of patents, and they count first filers only. They remain widely quoted, so read their date.

Brand and generic settlements are common, and the FTC reads them

FTC's newest report we found, for fiscal 2021, counts 199 final patent settlements between brand and generic companies, covering 86 branded products. In 33, the generic company accepted a restriction on marketing its product and received explicit compensation from the brand. In all 33, that compensation took the form of litigation fees, averaging $3.082 million.28

FTC's staff write that the Supreme Court in FTC v. Actavis (2013) "confirmed that patent settlements are subject to the antitrust laws and that some may be unlawful".29 A settlement is a decision for counsel with antitrust advice. It belongs on the same record as the suit decision, because the stay, the date and the terms are linked.

Inter partes review beside the notice: the Patent Office route has narrowed since 2025

In shortA challenger can also attack your patent at the Patent Trial and Appeal Board, through inter partes review (IPR). Since October 20, 2025 the Director decides whether a review begins. The Patent Office (USPTO) counts institution, the decision to begin a review, falling from 68% of petitions in fiscal 2024 to 41% in fiscal 2026, with bio and pharma petitions at 55%, and a final rule is pending. A filing at the Board does not change the 45 days. Orange Book patents are a small and shrinking share of these petitions.

Drug patents are a small part of the Board's work

We found no Orange Book count for the full fiscal 2026.

The final rule, RIN 0651-AD89, reached the White House regulatory office on July 22, 2026 and showed as pending on November 3, 2026.15

Fish & Richardson reads the proposal as adding bars where claims have already been upheld elsewhere and where parallel litigation will likely decide validity first, with an exception for extraordinary circumstances, and as requiring a stipulation giving up certain invalidity challenges elsewhere.32 Until it is published, treat this as a proposal, and watch it, because it bears directly on whether a generic can press the same obviousness arguments at the Board and in court.

The BPCIA patent dance under 42 USC 262(l): six exchanges, about 245 days and no 30-month stay

In shortBiosimilars, close copies of biologic medicines, run on a different law, the Biologics Price Competition and Innovation Act (BPCIA). The law calls the brand the reference product sponsor. The applicant may hand over its application, the two sides swap patent lists and detailed statements on fixed clocks, then a first suit is limited to patents they agree on or select. There is no Orange Book, no Paragraph IV and no automatic 30-month stay. The Supreme Court has held that the hand-over is not enforceable by federal injunction.

In Sandoz v. Amgen (2017) the Court also held that "the applicant may provide notice either before or after receiving FDA approval".10 Volumes are small: Fish & Richardson counts eight new complaints under this law in 2025, six of them on one molecule.34 A bill limiting patents in these suits to 20, S. 1041, passed the Senate on July 21, 2026 and was held at the House desk, so it is not law.16

Where a Paragraph IV response breaks before the complaint: eight errors and what prevents each

In shortNo source publishes how often patent teams miss a window or count it wrongly. The errors below come from the rule's own traps and from cases where they surfaced. The dangerous ones are simple: wrong start date, a letter that sat in a mailroom, a second recipient nobody checked, and a venue chosen too late.

The complaint still has to be true: Rule 11 inside a 45-day window

A short clock does not relax the duty on the lawyer who signs. Under Rule 11 of the federal civil rules, factual contentions must come from "an inquiry reasonable under the circumstances" and "have evidentiary support or, if specifically so identified, will likely have evidentiary support" after discovery.36 That is the practical reason for reading the detailed statement early and asking for the ANDA. It gives counsel something real to rest the complaint on, for every patent and claim. The days spent re-reading old arguments are days not spent on that inquiry.

What software can sort in a notice letter, and the legal calls on sufficiency, strength and suit

In shortThe repetitive parts suit software: reading a letter, extracting dates, splitting arguments, finding earlier answers, drafting from a record. Whether a notice is sufficient, whether an argument is strong and whether to sue are legal judgments, and they stay with patent counsel. Drug-specific AI rules mostly do not reach this work. Lawyers' duties and privilege do.

Why every date and argument needs its page beside it

The clearest public test did not study notice letters. Researchers found three commercial legal research tools produced false information between 17% and 33% of the time, on 2024 versions.45 We found no published accuracy study on detailed statements, so a vendor's figure is the vendor's own. In practice, a confident sentence is worth nothing here unless a person can open the page behind it. Five controls keep it open.

How a patent team answers a notice now: reception, paralegal, litigator, outside counsel and chief patent counsel

In shortA paralegal logs the receipt, a litigator reads the letter, outside counsel rebuilds a claim chart and searches old briefs, and chief patent counsel decides. Most of this moves through a docketing system, email, shared drives and a firm's document system. No study publishes how the days split, so the estimate below is only an illustration, and your own numbers should replace it.

The paralegal, the litigator, the coordinator, the firm and the chief

Three ways teams handle a Paragraph IV notice

A notice letter signed for at 8:41 am: the 314.95 check and the statutory clock, set the same morning

In shortLena Ortiz, litigation paralegal, confirms the courier receipt at 8:42 am. Dana Okafor, senior patent litigation counsel, clicks once. The agents check the letter and pass 8 of 8 checks, draw the 45-day window, and place the 30-month stay and the patents on one timeline. Nothing is final until a person has confirmed the receipt, and nothing is sent outside the company.

1

The letter is in, and the clock waits

The tab shows Jorvane Generics, ANDA 920455, received October 7 at 8:41 am. The clock says "clock not set". The receipt sits on the timeline at day 0, and the window will be drawn once the letter is read and found valid.

Brightwell Pharma's notice sits in the next tab. It came two days earlier, with 4 new arguments. Along the bottom, "Also running" lists the other clocks: a biosimilar application, a response, an IPR date and a trial.

2

Read the notice: eight checks, each with its page

The Notice Reader confirms that FDA's acknowledgment arrived September 30 and that the letter is dated October 5, five days later. It finds the ANDA number and product, the patents with their answers, a detailed statement on pages 9 to 27, the offer of confidential access, the receipt proof, and that no US contact is needed because Jorvane is a Delaware company.

It flags a defect and never fixes one.

3

The Clock Keeper draws one timeline on three scales

The first scale is days from receipt, with the litigation hold on October 9, the request for ANDA access on October 16, the target on November 20 and day 45. The second is the stay, to April 7, 2029. The third is the patents: '207 (the generic waits), '772 and '418.

Alerts are set at 30, 14, 7, 3 and 1 days, to Dana Okafor and Omar Haddad. The receipt line records who confirmed it.

4

Every clock for the matter, with the reason beside it

The matter's Clocks tab lists the hold (within 4 days, and day 4 is a Sunday, so October 9), the ANDA request (leaving 30 days to review) and the suit date. It marks each as internal or statutory, so nobody takes a house rule for the law.

It also notes that the Paragraph III answer holds Jorvane behind the '207 until March 15, 2033.

Mapping a detailed statement: nine arguments, eight claims, three earlier challengers and two surprises

In shortThe Contention Mapper splits pages 9 to 27 into nine arguments against eight claims of the '772 and '418. The Prior Positions Finder compares each with the earlier challenges from Holmbury Generics, Ivel Pharma and Brightwell Pharma. Five were answered before, two are answered by the company's own record, and two are new. Those two rise to the top with a next action and a named person.

5

Claims under attack, beside every earlier challenge

On the left, every claim of each patent, with chips for the grounds against it. Claims hit by a new argument are marked red. On the right, each argument in Jorvane's notice against Holmbury, Ivel and Brightwell.

The last column says what the company already has: "Voss reply report ¶¶ 84–97", "The court rejected it for Ivel on Aug 21, 2026", "Terminal disclaimer over the '546, filed Jul 18, 2017".

6

J7: releases 76% at 12 hours, below claim 9's 80%

The panel shows what Jorvane says, with its page, and the assessment: new and fact-dependent, ask for the ANDA dissolution data under confidential access. One button sends that request to the formulation expert.

The other new one, J9, says the 10 mg strength is not described. The record shows Example 3 tablets are 10 mg, and counsel is asked to confirm the wording.

7

Click a claim to see only what attacks it

Choosing claim 14 of the '418 cuts the map to the two arguments against it: J9, new, and J5, a repeat of Holmbury's review grounds. That is how a litigator tests one claim's exposure before deciding which claims to assert.

8

Every argument against every claim, with the letter open beside it

Matter M-2615 opens as a claim-by-ground chart with columns for not infringed, no inducement, anticipated, obvious, indefinite or not described, and double patenting. J7 and J9 are in red. The notice sits alongside, highlighted where the reader took each fact, and any cell opens its page.

The sample numbers on the letter, such as 90,477,772, are deliberately outside the range of real patents.

9

Brightwell's notice shows what real news looks like

Brightwell's letter carries a reference nobody had raised: a November 2013 congress abstract by Kessler and colleagues, on 10 mg once daily in 48 patients. The file history shows the examiner never saw it, and Holmbury and Ivel never relied on it. It also says nothing about eGFR, a kidney function test, or beta-blockers, so claims 7 and 11 stand clear of it, on the agent's reading.

That is the argument that earns counsel's week. The next step goes to outside counsel for a validity read.

The litigation hold, the outside counsel briefing and the signature that patent counsel keeps

In shortThe Response Pack Drafter writes the hold and the briefing from the matter's own record, every statement cited, every page stamped privileged. Dana Okafor signs the hold. Sam Patel releases the briefing. Omar Haddad, chief patent counsel, reads the options and signs the suit decision. The agents recommend. They do not decide, and they never file.

10

A hold for 31 custodians, and a briefing that says what is new

The hold goes to the same 31 custodians as the Brightwell hold, plus Jorvane-specific correspondence owners, and adds dissolution work on polyethylene-oxide matrices. Acknowledgments are due October 14, and Lena Ortiz tracks them.

The briefing to the fictional firm Whitcombe & Rowe has four parts: the matter, what is new, what is already answered, and what is asked. It asks the firm to consider joining Jorvane to the Brightwell complaint in Delaware, and budgets the first pass at 25 hours.

11

Four options, and one signature

The decision screen shows the days left, the stay and four options: sue on '772 and '418 in Delaware, related to the Brightwell case (recommended, since Jorvane is a Delaware company); ask for the ANDA first, then sue; sue on '772 only; or do not sue and keep watching.

The note to outside counsel names the claims to assert and asks for the ANDA to test the 76% figure. The decision belongs to Omar Haddad.

12

Signed, on the audit trail

Omar signs. The banner records the decision, the firm and the date, the matter moves to the next stage, and the signature goes on the audit trail. The firm files the complaint. The applicant must then tell FDA within 14 days, and the patent owner may do so too.4

Another counsel could read the same record and choose differently

The screens show one company's choices. A different counsel could sue only on one patent, or wait for the ANDA, and neither would be wrong on these facts. What the record gives them is the same: the clock, the claims, what is new and what it costs to wait.

Six notice agents, the people who sign, and how biosimilar matters and trials sit beside Paragraph IV

In shortBeyond the single notice, the team sees all its matters and clocks on one screen, biosimilar matters with their patent dance steps, cases already in suit with their review petitions, and a dashboard of which arguments come back. Six specialist agents read, count, map, compare, draft and track. People confirm, sign and decide. Outcome numbers here are design targets.

What each notice agent does, and where it stops

Who confirms a receipt, who releases a briefing and who decides to sue

The sample team, in the words they use about notices

From a courier envelope and a litigation record to a signed decision

The systems a notice already touches

Privilege, restricted material and the controls your counsel will ask about

The time the design aims to take out of the first response

Design targets in the solution's data: 0.4 days from receipt to the first-response pack, and 64% of a challenger's arguments answered from your own past record. Your share depends on how many earlier challenges you have. On a first notice, it may be close to zero.

What a missed day 45 and a repeated first read cost a brand's patent team

In shortTwo costs sit here, of very different sizes. A missed window costs the automatic stay, and possibly years of sales, on a rare and severe bad day. A repeated first read costs outside counsel hours on every notice, every time. Almost none of this is published. So treat public figures as context, and take a week to measure your own.

The newest survey numbers we could read are a law firm's October 2025 slide reprinting the American Intellectual Property Law Association's medians for 2022: with pre-trial, post-trial and any appeal, $5.25 million for Hatch-Waxman cases with $10 million to $25 million at risk, and $3 million above $25 million at risk, against $3.5 million and $5 million in 2018 and 2020.46,47 The bands swing and even cross, so read them as rough. The survey's 2025 report is for members, and we did not read it. Ask your firm for your own totals.

Six notice costs you can measure in a week, starting with three past letters

What a thin first read does that no invoice shows

What notice automation returns: first-pass hours, days back in the window and one record of every answer

In shortPut in your own numbers. The first calculator values first-pass hours released on each notice. The second is kept apart: it sizes what a stay protects on one product, as an order of magnitude to discuss with counsel and finance. We never add the two, because a tool does not earn the value of a stay. Defaults are illustrative, and a pilot should replace them.

Where a Paragraph IV first response gets faster: the statement, old answers, the drafts and the dates

First-pass hours calculator: notices a year, firm hours and your team's time

One product's 30-month stay, sized for a conversation with finance

Score your patent team on receipt proof, the litigation record, confidential access and who signs

In shortPick the answer closest to your team today. Eight questions score 0 to 2, and the last is for reflection. The meter adds up your score as you go, and each question says why it matters and what a strong answer sounds like.

Twelve questions for any Paragraph IV notice management vendor, us included

In shortA date engine is easy to demonstrate. These questions test what a demonstration hides: whether the count follows FDA's rule, whether an "answered" label points at a real page, who may see restricted material, and what happens to privilege.

Testing notice software in eight weeks: a closed letter, hidden new arguments and one live notice in parallel

In shortStart with a closed notice you know well, so you can see whether the tool finds what your team found, and what it missed. Hide a new argument to test the comparison. Then run one live notice beside your usual process, under counsel's direction, with your docket remaining the system of record until you decide on five measures.

Missed new arguments, false alarms and days left at decision on your own notice

Paragraph IV questions answered: the 45 days, the 30-month stay, notice letters, venue and AI

In shortThe questions people search about Paragraph IV notices, each answered on its own in plain words. General information, as of November 2026. Your counsel's advice comes first.